Phaseline

Targets › PDK2

PDK2 ([Pyruvate dehydrogenase): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine, Oncology.

Kinase that plays a key role in the regulation of glucose and fatty acid metabolism and homeostasis via phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation of acetyl-coenzyme A from pyruvate. (UniProt, Q15119)

Open in Phaseline: the race on PDK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Saol TherapeuticsSodium Dichloroacetate
Pyruvate dehydrogenase kinase inhibitor
PDK2, PDK3, PDK4, PDK1Phase 3Pyruvate Dehydrogenase Complex Deficiency; Glioblastoma Multiforme–

Conditions

Pyruvate Dehydrogenase Complex Deficiency (1) Glioblastoma Multiforme (1)

Modalities

mixed (1)

Companies

Saol Therapeutics (1)

Related targets

PDK3 (1) PDK4 (1) PDK1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.